Orchestrating the metastatic symphony: the role of extracellular vesicles in the epithelial-mesenchymal transition and pulmonary niche formation of breast cancer.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Orchestrating the metastatic symphony: the role of extracellular vesicles in the epithelial-mesenchymal transition and pulmonary niche formation of breast cancer.
Συγγραφείς:	Lu J; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Shirazi Nia R; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Sun J; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China., Filippopoulou C; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., De Vega D; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Hu P; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China., Liang H; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Yao H; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Pan C; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Wu X; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Gu X; Department of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Xie X; Department of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China., Giamas G; International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310053, China.; Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK.
Πηγή:	Biological reviews of the Cambridge Philosophical Society [Biol Rev Camb Philos Soc] 2026 Oct; Vol. 101 (5), pp. 2103-2118. Date of Electronic Publication: 2026 Apr 02.
Τύπος έκδοσης:	Journal Article; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Cambridge University Press Country of Publication: England NLM ID: 0414576 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-185X (Electronic) Linking ISSN: 00063231 NLM ISO Abbreviation: Biol Rev Camb Philos Soc Subsets: MEDLINE
Imprint Name(s):	Original Publication: London, Cambridge University Press.
Ιατρικοί όροι (MeSH):	Epithelial-Mesenchymal Transition/physiology , Extracellular Vesicles/physiology , Breast Neoplasms/pathology , Lung Neoplasms/secondary, Humans ; Animals ; Female ; Tumor Microenvironment ; Neoplasm Metastasis
Περίληψη:	The complexity of breast cancer (BC) lung metastasis lies in the capacity of tumour cells to interact efficiently with distant organs to promote colonisation, a process that involves the sophisticated coordination of inherent cellular plasticity and the remodelling of the distant microenvironment. This review emphasises the essential function of extracellular vesicles (EVs) within this communication network. Tumour-derived EVs (TEVs) not only induce epithelial-mesenchymal transition (EMT) by reprogramming breast cancer cell gene expression networks, thereby enhancing migratory and invasive capabilities, but also serve as a 'vanguard', arriving in the lungs in advance to educate stromal cells and establish a pre-metastatic niche that facilitates breast cancer progression. This review uniquely conceptualises EV-mediated EMT and niche formation as a synergistic and sequential biological continuum. We comprehensively examine the sorting mechanisms of EV molecular cargo, targeted delivery approaches, and hierarchical regulatory networks. Critically, we propose that the concurrent regulation of EMT and niche formation is likely driven by the synergistic action of distinct EV subpopulations rather than single 'multitasking' vesicles. Future investigations dissecting this heterogeneity will be pivotal for verifying this synergistic subpopulations hypothesis and establishing a theoretical basis for precise EV-based metastasis intervention strategies. (© 2026 The Author(s). Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.)
References:	Cell Death Discov. 2021 Jul 8;7(1):176. (PMID: 34238918) Mol Cancer. 2025 Jun 23;24(1):183. (PMID: 40551109) Int J Mol Sci. 2025 Jun 06;26(12):. (PMID: 40564894) Cell Res. 2018 Aug;28(8):862-864. (PMID: 29959401) Nature. 2025 Feb;638(8049):244-250. (PMID: 39743589) Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6740-5. (PMID: 17420468) Cell. 2023 Apr 13;186(8):1564-1579. (PMID: 37059065) Int J Biol Sci. 2024 Oct 14;20(14):5695-5714. (PMID: 39494337) J Extracell Vesicles. 2021 Jul;10(9):e12125. (PMID: 34295457) Adv Mater. 2025 Feb;37(5):e2411259. (PMID: 39659120) Front Immunol. 2024 Mar 12;15:1302587. (PMID: 38533507) Cell Commun Signal. 2020 Sep 25;18(1):158. (PMID: 32988382) Molecules. 2024 Oct 01;29(19):. (PMID: 39407601) Proteomics. 2024 Jun;24(11):e2300180. (PMID: 37713108) J Pathol. 2019 Aug;248(4):421-437. (PMID: 30982971) Oncogene. 2023 Oct;42(41):3017-3034. (PMID: 37670020) Trends Cell Biol. 2023 Aug;33(8):667-681. (PMID: 36737375) Nat Commun. 2018 Oct 15;9(1):4256. (PMID: 30323298) Signal Transduct Target Ther. 2023 May 8;8(1):182. (PMID: 37150786) Lab Chip. 2022 Jun 28;22(13):2502-2518. (PMID: 35579189) Mol Cancer. 2023 Feb 16;22(1):33. (PMID: 36797736) Breast Cancer Res. 2022 Sep 12;24(1):60. (PMID: 36096830) Semin Cancer Biol. 2022 Dec;87:196-213. (PMID: 36371024) Theranostics. 2022 May 13;12(9):4127-4146. (PMID: 35673569) Cell Commun Signal. 2023 Sep 28;21(1):266. (PMID: 37770930) Nature. 2025 Jul;643(8072):801-809. (PMID: 40500450) J Extracell Vesicles. 2024 Feb;13(2):e12404. (PMID: 38326288) J Extracell Vesicles. 2023 Feb;12(2):e12299. (PMID: 36759917) Oncogene. 2021 Feb;40(6):1043-1063. (PMID: 33420366) Cancer Lett. 2013 Sep 10;338(1):63-8. (PMID: 22634497) Nat Rev Cancer. 2023 Jan;23(1):25-42. (PMID: 36385560) Adv Sci (Weinh). 2024 Aug;11(30):e2401069. (PMID: 38874129) Signal Transduct Target Ther. 2024 Feb 5;9(1):27. (PMID: 38311623) Prostaglandins Leukot Essent Fatty Acids. 2014 Dec;91(6):299-310. (PMID: 25301203) Cancer Res. 2010 Dec 1;70(23):9621-30. (PMID: 21098712) Oncogene. 2020 Jun;39(23):4477-4490. (PMID: 32366909) Cancer Commun (Lond). 2022 Oct;42(10):1036-1040. (PMID: 35881673) Cancer Cell. 2024 Jun 10;42(6):1018-1031.e6. (PMID: 38821060) J Exp Clin Cancer Res. 2024 Jan 16;43(1):20. (PMID: 38229152) Nature. 2015 Nov 19;527(7578):329-35. (PMID: 26524530) Cell Biol Toxicol. 2022 Oct;38(5):725-740. (PMID: 34460027) Nat Rev Cancer. 2025 Jul;25(7):545-560. (PMID: 40263543) Nat Commun. 2022 Aug 1;13(1):4461. (PMID: 35915084) Mol Cancer. 2024 Sep 7;23(1):191. (PMID: 39244548) Mol Cancer. 2019 Dec 3;18(1):175. (PMID: 31796058) Mol Ther Nucleic Acids. 2020 Mar 6;19:654-667. (PMID: 31955007) Trends Cell Biol. 2025 Mar;35(3):230-247. (PMID: 39327161) Adv Mater. 2023 Mar;35(13):e2208966. (PMID: 36609913) Cancer Sci. 2024 Feb;115(2):347-356. (PMID: 38129137) Anal Chem. 2020 Aug 4;92(15):10274-10282. (PMID: 32631050) J Exp Clin Cancer Res. 2025 May 23;44(1):157. (PMID: 40410902) Nat Cell Biol. 2019 Feb;21(2):190-202. (PMID: 30598531) Gene. 2024 Jan 20;892:147873. (PMID: 37832808) J Adv Res. 2025 Jul;73:645-657. (PMID: 39197817) Semin Cancer Biol. 2022 Nov;86(Pt 1):112-126. (PMID: 35032650) Immunity. 2022 Aug 9;55(8):1336-1339. (PMID: 35947977) Int J Oral Sci. 2023 Aug 2;15(1):32. (PMID: 37532712) Nat Cell Biol. 2010 Mar;12(3):247-56. (PMID: 20173740) Mol Cancer. 2024 Jan 19;23(1):18. (PMID: 38243280) Clin Cancer Res. 2016 Sep 1;22(17):4517-24. (PMID: 27060153) Int J Mol Sci. 2021 Jan 09;22(2):. (PMID: 33435297) Cancer Cell. 2016 Dec 12;30(6):836-848. (PMID: 27960084) Signal Transduct Target Ther. 2020 Mar 12;5(1):28. (PMID: 32296047) Cell Death Dis. 2023 Jul 26;14(7):471. (PMID: 37495592) Cancer Res. 2024 Oct 1;84(19):3267-3285. (PMID: 38900939) ACS Nano. 2021 Nov 23;15(11):18192-18205. (PMID: 34735133) Mol Cancer. 2024 Apr 25;23(1):82. (PMID: 38664722) Mol Cell Proteomics. 2025 Dec;24(12):101028. (PMID: 40618999) BMC Cancer. 2023 Oct 5;23(1):939. (PMID: 37798728) Trends Cell Biol. 2022 Apr;32(4):285-294. (PMID: 34895986) Nat Cell Biol. 2015 Feb;17(2):183-94. (PMID: 25621950) Anal Chem. 2023 Jan 6;:. (PMID: 36608325) Int J Mol Sci. 2023 Feb 11;24(4):. (PMID: 36835073) Front Immunol. 2024 Feb 26;15:1344681. (PMID: 38469310) Nat Rev Cancer. 2024 Dec;24(12):829-849. (PMID: 39390247) Cancer Lett. 2021 Dec 28;523:43-56. (PMID: 34601021) Front Immunol. 2018 Nov 29;9:2787. (PMID: 30555472) Biomolecules. 2022 Jan 14;12(1):. (PMID: 35053279) Nature. 2009 Jun 18;459(7249):1005-9. (PMID: 19421193) Cancer Lett. 2024 Nov 1;604:217199. (PMID: 39216547) Mol Cancer. 2025 Apr 16;24(1):118. (PMID: 40241074) Oncogene. 2021 Aug;40(31):4992-5001. (PMID: 34172932) Cancer Discov. 2023 Dec 12;13(12):2610-2631. (PMID: 37756565) Mol Cancer. 2024 Oct 11;23(1):227. (PMID: 39390584) Cell Death Dis. 2021 Dec 1;12(12):1120. (PMID: 34853307) Theranostics. 2021 Feb 6;11(8):3932-3947. (PMID: 33664871) Mol Cancer. 2019 Mar 30;18(1):58. (PMID: 30925921) Oncogene. 2023 Oct;42(44):3236-3251. (PMID: 37717099) Theranostics. 2017 Aug 23;7(15):3700-3714. (PMID: 29109770) Cancer Res. 2017 Nov 1;77(21):5846-5859. (PMID: 28720577) iScience. 2023 Mar 21;26(4):106482. (PMID: 37091228) Adv Sci (Weinh). 2025 Jan;12(4):e2310266. (PMID: 39630109) Int J Mol Sci. 2020 Apr 27;21(9):. (PMID: 32349218) Pharmacol Res. 2023 Feb;188:106669. (PMID: 36681367) Front Pharmacol. 2022 Mar 31;12:800481. (PMID: 35431911) Theranostics. 2019 Jun 9;9(15):4494-4507. (PMID: 31285775) Front Immunol. 2018 Apr 30;9:738. (PMID: 29760691) Sci Rep. 2020 Aug 7;10(1):13327. (PMID: 32770003) Signal Transduct Target Ther. 2025 Feb 21;10(1):57. (PMID: 39979279) Mol Cancer. 2025 Mar 08;24(1):72. (PMID: 40057730) Cancer Cell Int. 2024 Dec 18;24(1):402. (PMID: 39696346) Signal Transduct Target Ther. 2024 Dec 18;9(1):352. (PMID: 39690159) Cell Mol Biol Lett. 2022 Oct 9;27(1):88. (PMID: 36210461) J Extracell Vesicles. 2023 Jul;12(7):e12346. (PMID: 37422692) Biochem Pharmacol. 2021 Oct;192:114714. (PMID: 34332957) J Extracell Vesicles. 2021 Nov;10(13):e12167. (PMID: 34796683) Acta Pharm Sin B. 2021 Sep;11(9):2783-2797. (PMID: 34589397)
Contributed Indexing:	Keywords: breast cancer; cell–cell communication; epithelial–mesenchymal transition; exosomes; extracellular vesicles; lung metastasis; molecular sorting; organotropism; pre‐metastatic niche
Entry Date(s):	Date Created: 20260402 Date Completed: 20260904 Latest Revision: 20260906
Update Code:	20260906
PubMed Central ID:	PMC13542348
DOI:	10.1002/brv.70167
PMID:	41923477
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1469-185X
DOI:	10.1002/brv.70167